FDA Approves Artesunate For Injection To Treat Severe Malaria

CDC: FDA Approval of Artesunate for Injection for Treatment of Severe Malaria
“Artesunate for InjectionTM was approved by the FDA on May 26, 2020 for treatment of severe malaria. … Previously, the only intravenous (IV) antimalarial available to treat severe malaria in the United States was investigational IV artesunate solely available from CDC through an expanded-use investigational new drug (IND) protocol. With FDA approval, and soon, commercial availability, hospitals will be able to stock IV artesunate for immediate treatment of patients with severe malaria to prevent poor outcomes such as death. Until Artesunate for Injection is commercially available, CDC will continue to make IV artesunate available through the IND protocol…” (5/28).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.